SN.L Stock Analysis
SN
Neutral
Based on Eyestock quantitative analysis, SN.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
13.546
Dividend yield
4.67 %
Shares outstanding
870.16 B
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 19,012 full-time employees. The firm is engaged in developing, manufacturing, marketing and selling medical devices and services. The company is focused on the repair, regeneration and replacement of soft and hard tissue. The firm operates through three segments: Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that helps surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.